Neuro oncology News and Research

RSS

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell.

26 Nov 2009

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body.

18 Nov 2009

UT Southwestern Medical Center awarded $42M for basic and patient-oriented research

UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.

13 Nov 2009

First evidence-based, multidisciplinary treatment guidelines for brain metastases patients to be published

Anthony Asher, MD, FACS, of Carolina Neurosurgery & Spine Associates in Charlotte, NC, has co-authored the first evidence-based, multidisciplinary treatment guidelines for brain metastases patients. These guidelines were recently presented at the Congress of Neurological Surgeons 2009 Annual Meeting in New Orleans, and were developed over the last year by a 20-member panel from various medical specialties.

11 Nov 2009

Men more likely to abandon partners diagnosed with cancer

A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact.

11 Nov 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

Medtronic announces the international launch of PoleStar N30 Surgical MRI system

This week at the annual Congress of Neurological Surgeons (CNS), Medtronic (NYSE: MDT) announced the Conformite Europeen (CE) mark and international launch of the PoleStar® N30 Surgical MRI system, the latest in neuro oncology surgical solutions.

28 Oct 2009

New significant tool to improve the quality of care for patients with brain tumors released

While the nation is debating how best to reform healthcare, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) announce a new significant tool to improve the quality of care for patients who suffer from brain tumors.

27 Oct 2009

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

26 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

Elekta to demonstrate stereotactic solutions at the 2009 CNS Annual Meeting

At the 2009 Congress of Neurological Surgeons (CNS) Annual Meeting, October 24-28 in New Orleans, Louisiana, Elekta will demonstrate how its line of stereotactic solutions expand treatment capabilities and bring new hope for patients presenting serious conditions.

From Elekta 24 Oct 2009

John Muir Health earns Network Cancer Program accreditation

John Muir Health’s Walnut Creek and Concord campuses have earned a three-year accreditation with commendation as a Network Cancer Program (NCP) from the American College of Surgeons Commission on Cancer (CoC), a consortium of professional organizations dedicated to improving survival and quality of life for cancer patients. John Muir Health is one of only two hospitals in California and the only one in the San Francisco Bay Area to receive the recognition.

24 Oct 2009

Updated data on XL184 study in patients with glioblastoma multiforme presented

Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

24 Oct 2009

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, today announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound 131I-TM601 in the treatment of recurrent malignant glioma.

24 Oct 2009

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

19 Oct 2009

Cancer Genome Atlas funds study for analysis and interpretation of tumor genetic data

The Cancer Genome Atlas (TCGA) will fund an effort by scientists at The University of Texas M. D. Anderson Cancer Center to siphon buckets of meaningful information from an ocean of data about the aberrant genetics that drive human cancers.

8 Oct 2009

Research study reveals primary chemotherapy benefits

Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.

3 Oct 2009

Avastin increases survival rates in recurrent glioblastoma affected patients

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.

3 Sep 2009

Neuro oncology News and Research

Clinical trials of personalised vaccines to fight glioblastomas

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

UT Southwestern Medical Center awarded $42M for basic and patient-oriented research

First evidence-based, multidisciplinary treatment guidelines for brain metastases patients to be published

Men more likely to abandon partners diagnosed with cancer

Third-quarter 2009 financial results of Antigenics announced

Medtronic announces the international launch of PoleStar N30 Surgical MRI system

New significant tool to improve the quality of care for patients with brain tumors released

Results from Phase I dose-escalation study of AT-101 announced

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Elekta to demonstrate stereotactic solutions at the 2009 CNS Annual Meeting

John Muir Health earns Network Cancer Program accreditation

Updated data on XL184 study in patients with glioblastoma multiforme presented

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Cancer Genome Atlas funds study for analysis and interpretation of tumor genetic data

Research study reveals primary chemotherapy benefits

Avastin increases survival rates in recurrent glioblastoma affected patients

Cancer Research eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News